Lunit Collaborates to Enhance Immunotherapy with AI

30th October, 2023

Lunit to support MD Anderson researchers studying immune phenotype biomarkers for pembrolizumab treatment response

Lunit AI-powered TIL analyzer, Lunit SCOPE IO

Lunit AI-powered TIL analyzer, Lunit SCOPE IO

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a research collaboration with The University of Texas MD Anderson Cancer Center to analyze the use of Merck's (known as MSD outside the US and Canada) Keytruda (pembrolizumab), a type of immunotherapy drug used in cancer treatment, in multiple cancer types. The project will use Lunit's proprietary AI solution for tissue data analysis, Lunit SCOPE IO.

Artificial Intelligence Breakthroughs

Robots In Medtech

Asia Pacific

Global / International

© 2023 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer